{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T01:50:15Z","timestamp":1768269015693,"version":"3.49.0"},"reference-count":13,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"name":"Clinical Research Project of Women's Hospital, Zhejiang University School of Medicine","award":["ZDFY2022-4X201"],"award-info":[{"award-number":["ZDFY2022-4X201"]}]},{"name":"Zhejiang Provincial Natural Science Foundation of China"}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1136\/ijgc-2023-004978","type":"journal-article","created":{"date-parts":[[2023,12,30]],"date-time":"2023-12-30T09:00:11Z","timestamp":1703926811000},"page":"328-331","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Secondary cytoreduction surgery for recurrent epithelial ovarian cancer patients after PARPi maintenance: A multicenter, randomized, controlled clinical trial"],"prefix":"10.1016","volume":"34","clinical-trial-number":[{"clinical-trial-number":"nct05607329","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0233-9369","authenticated-orcid":false,"given":"Tingting","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2377-0775","authenticated-orcid":false,"given":"Junfen","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bairong","family":"Xia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0474-3472","authenticated-orcid":false,"given":"Yuanming","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1136\/ijgc-2023-004978_bb0010","first-page":"17","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J Clin"},{"key":"10.1136\/ijgc-2023-004978_bb0015","article-title":"Treatment of epithelial ovarian cancer","volume":"371","author":"Kuroki","year":"2020","journal-title":"BMJ"},{"key":"10.1136\/ijgc-2023-004978_bb0020","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.annonc.2022.06.011","article-title":"Efficacy of subsequent chemotherapy for patients with Brca1\/2-mutated recurrent epithelial ovarian cancer progressing on olaparib versus placebo maintenance: post-hoc analyses of the Solo2\/ENGOT Ov-21 trial","volume":"33","author":"Frenel","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1136\/ijgc-2023-004978_bb0025","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ejca.2023.03.035","article-title":"Cytoreductive surgery for advanced epithelial ovarian cancer in the poly(ADP-ribose) polymerase inhibitors era-is it time for a new paradigm shift? A systematic review and meta-analysis","volume":"187","author":"Peters","year":"2023","journal-title":"Eur J Cancer"},{"key":"10.1136\/ijgc-2023-004978_bb0030","doi-asserted-by":"crossref","first-page":"3528","DOI":"10.1200\/JCO.20.00799","article-title":"Efficacy of maintenance olaparib for patients with newly diagnosed advanced ovarian cancer with a BRCA mutation: subgroup analysis findings from the Solo1 trial","volume":"38","author":"DiSilvestro","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2023-004978_bb0035","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1016\/S1470-2045(21)00531-3","article-title":"Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (Solo1\/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"22","author":"Banerjee","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1136\/ijgc-2023-004978_bb0040","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S1470-2045(21)00006-1","article-title":"Secondary cytoreduction followed by chemotherapy versus chemotherapy alone in platinum-sensitive relapsed ovarian cancer (SOC-1): a multicentre, open-label, randomised, phase 3 trial","volume":"22","author":"Shi","year":"2021","journal-title":"Lancet Oncol"},{"issue":"15_suppl","key":"10.1136\/ijgc-2023-004978_bb0045","doi-asserted-by":"crossref","first-page":"6000","DOI":"10.1200\/JCO.2020.38.15_suppl.6000","article-title":"Randomized phase III study to evaluate the impact of secondary cytoreductive surgery in recurrent ovarian cancer: final analysis of AGO DESKTOP III\/ENGOT-Ov20","volume":"38","author":"Du Bois","year":"2020","journal-title":"JCO"},{"key":"10.1136\/ijgc-2023-004978_bb0050","article-title":"Clinical application of radiotherapy in patients with oligometastatic ovarian cancer: a sharp tool to prolong the interval of systemic treatment","volume":"13","author":"Shen","year":"2022","journal-title":"Discov Oncol"},{"key":"10.1136\/ijgc-2023-004978_bb0055","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1093\/annonc\/mdu370","article-title":"Phase II study of stereotactic body radiotherapy to primary tumor and metastatic locations in oligometastatic nonsmall-cell lung cancer patients","volume":"25","author":"Collen","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1136\/ijgc-2023-004978_bb0060","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-017-3341-2","article-title":"Oligometastases from prostate cancer: local treatment with stereotactic body radiotherapy (SBRT)","volume":"17","author":"Habl","year":"2017","journal-title":"BMC Cancer"},{"key":"10.1136\/ijgc-2023-004978_bb0065","doi-asserted-by":"crossref","first-page":"2968","DOI":"10.1200\/JCO.18.02238","article-title":"Niraparib maintenance therapy in patients with recurrent ovarian cancer after a partial response to the last platinum-based chemotherapy in the ENGOT-Ov16\/NOVA trial","volume":"37","author":"Del Campo","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2023-004978_bb0070","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14184414","article-title":"Multicenter real-world data of subsequent chemotherapy after progression to PARP inhibitors in a maintenance relapse setting","volume":"14","author":"Romeo","year":"2022","journal-title":"Cancers (Basel)"}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24012970?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24012970?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ijgc-2023-004978","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T17:12:48Z","timestamp":1761844368000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X24012970"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":13,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["S1048891X24012970"],"URL":"https:\/\/doi.org\/10.1136\/ijgc-2023-004978","relation":{},"ISSN":["1048-891X"],"issn-type":[{"value":"1048-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Secondary cytoreduction surgery for recurrent epithelial ovarian cancer patients after PARPi maintenance: A multicenter, randomized, controlled clinical trial","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ijgc-2023-004978","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 IGCS and ESGO 2024. No commercial re-use. See rights and permissions. Published by BMJ.","name":"copyright","label":"Copyright"}]}}